[go: up one dir, main page]

PE20090357A1 - Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3 - Google Patents

Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3

Info

Publication number
PE20090357A1
PE20090357A1 PE2008000323A PE2008000323A PE20090357A1 PE 20090357 A1 PE20090357 A1 PE 20090357A1 PE 2008000323 A PE2008000323 A PE 2008000323A PE 2008000323 A PE2008000323 A PE 2008000323A PE 20090357 A1 PE20090357 A1 PE 20090357A1
Authority
PE
Peru
Prior art keywords
alkylene
alkyl
oxazol
octane
hydroxy
Prior art date
Application number
PE2008000323A
Other languages
English (en)
Inventor
Barbara Giuseppina Avitabile
Harry Finch
Jamie David Knight
Alan John Nadin
Nicholas Charles Ray
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0702994A external-priority patent/GB0702994D0/en
Priority claimed from GB0722678A external-priority patent/GB0722678D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of PE20090357A1 publication Critical patent/PE20090357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE R2 ES H, -(Z)p-R7, -Z-Y-R7 O -Y-R7; p ES 0 O 1; R4 Y R5 ES ALQUILO C1-C6, ARILO, CICLOALQUILO, ENTRE OTROS; R6 ES OH, ALQUILO C1-C6, ALCOXI C1-C6, NITRILO, ENTRE OTROS; UNO DE W, V Y A ES N O NR11; OTRO DE W, V Y A SON N, O, S O CR8; Y OTRO DE W, V Y A ES N O CR8; X ES ALQUILENO C1-C4, ALQUENILENO C2-C4 O ALQUINILENO C2-C4; R7 ES ALQUILO C1-C6, ALQUENILO C2-C6, ARILO, ENTRE OTROS; t, u Y v SON 1, 2 O 3, Z ES ALQUILENO C1-C4, ALQUENILENO C2-C4, ALQUINILENO C2-C4; Y ESO, -OC(O)-, N(H)C(O) O S(O)n; n ES UN ENTERO DE 0 A 2; R8 Y R11 SON H O ALQUILO C1-C6; D- ES UN CONTRAION. SON COMPUESTOS PREFERIDOS: 1-[2-(HIDROXI-DIFENIL-METIL)-OXAZOL-5-ILMETIL]-3-FENOXI-1-AZONIABICICLO[2,2,2]OCTANO, (R)-1-[2-((R)-CICLOHEXIL-HIDROXI-FENIL-METIL)-OXAZOL-5-ILMETIL]-3-FENOXI-1-AZONIA-BICICLO[2,2,2]OCTANO, (R)-3-BENCILOXI-1-[2-((R)-CICLOHEXIL-HIDROXI-FENIL-METIL)-OXAZOL-5-ILMETIL]-1-AZONIA-BICICLO[2,2,2]-OCTANO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS ACTUAN SOBRE LOS RECEPTORES MUSCARINICOS M3 Y SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA, ASMA, BRONQUITIS CRONICA, ENTRE OTRAS
PE2008000323A 2007-02-15 2008-02-14 Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3 PE20090357A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0702994A GB0702994D0 (en) 2007-02-15 2007-02-15 Compound and thier use
GB0722678A GB0722678D0 (en) 2007-11-19 2007-11-19 Compounds and their use II

Publications (1)

Publication Number Publication Date
PE20090357A1 true PE20090357A1 (es) 2009-04-01

Family

ID=39323641

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000323A PE20090357A1 (es) 2007-02-15 2008-02-14 Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3

Country Status (21)

Country Link
US (1) US20100056565A1 (es)
EP (1) EP2121688A1 (es)
JP (1) JP2010519193A (es)
KR (1) KR20090110353A (es)
CN (1) CN101657452A (es)
AR (1) AR065344A1 (es)
AU (1) AU2008215924B2 (es)
BR (1) BRPI0807913A2 (es)
CA (1) CA2676581A1 (es)
CL (1) CL2008000474A1 (es)
CO (1) CO6190612A2 (es)
EC (1) ECSP099573A (es)
IL (1) IL199971A0 (es)
MX (1) MX2009008323A (es)
NZ (1) NZ578489A (es)
PE (1) PE20090357A1 (es)
RU (1) RU2009133258A (es)
SA (1) SA08290066B1 (es)
TW (1) TW200843759A (es)
UY (1) UY30916A1 (es)
WO (1) WO2008099186A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
AU2009282521A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab 2-hydroxy-ethanesulfonate salt
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
ES2736098T3 (es) * 2014-08-26 2019-12-26 Astellas Pharma Inc Derivados de 2-aminotiazol o sal de los mismos como ligandos muscarínicos M3 para el tratamiento de enfermedades de la vejiga

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88846A0 (en) * 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
DK1353919T3 (da) * 2000-12-28 2006-11-20 Almirall Prodesfarma Ag Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme
RU2323218C2 (ru) * 2002-09-30 2008-04-27 НьюроСёрч А/С Новые производные 1,4-диазабициклоалкана и фармацевтическая композиция на их основе
US7220741B2 (en) * 2002-09-30 2007-05-22 Neurosearch A/S 1,4-diazabicycloalkane derivatives, their preparation and use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses

Also Published As

Publication number Publication date
JP2010519193A (ja) 2010-06-03
RU2009133258A (ru) 2011-03-20
WO2008099186A1 (en) 2008-08-21
ECSP099573A (es) 2009-12-28
KR20090110353A (ko) 2009-10-21
IL199971A0 (en) 2010-04-15
AU2008215924A1 (en) 2008-08-21
WO2008099186A8 (en) 2008-11-13
EP2121688A1 (en) 2009-11-25
CL2008000474A1 (es) 2008-08-22
US20100056565A1 (en) 2010-03-04
NZ578489A (en) 2011-05-27
MX2009008323A (es) 2009-08-13
BRPI0807913A2 (pt) 2014-06-17
UY30916A1 (es) 2008-09-30
AU2008215924B2 (en) 2011-04-21
CO6190612A2 (es) 2010-08-19
TW200843759A (en) 2008-11-16
CN101657452A (zh) 2010-02-24
SA08290066B1 (ar) 2011-05-14
CA2676581A1 (en) 2008-08-21
AR065344A1 (es) 2009-06-03

Similar Documents

Publication Publication Date Title
PE20090357A1 (es) Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
PE20090772A1 (es) Derivados de bencimidazol
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20071223A1 (es) Procedimiento de preparacion de derivados de acil-amino-alquilen-amida
ECSP066976A (es) 4-fenilamino-quinazolin-6-il-amidas
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
MXPA05004188A (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos.
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
CO6150149A2 (es) Compuestos azabiciclicos como inhibidfores de la recaptacion de monoaminas
MX2010003849A (es) Antagonistas de cgrp.
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
NO20071314L (no) Peptidiske vasopressinreseptoragonister

Legal Events

Date Code Title Description
FC Refusal